Chuikyo Debate on Off-Year Drug Price Revisions

• MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
  March 7, 2025

• Gist of FY2025 Drug Price Revision
  December 26, 2024

• Chuikyo OKs Outline of FY2025 Off-Year Drug Price Revision
  December 26, 2024

• Off-Year Price Revision to Hit 53% of Listed Drugs in 2025, Down from 69%
  December 23, 2024

• MHLW Proposes Setting Product Scope for Off-Year Revisions by Category
  December 19, 2024

• MHLW to Disclose Company Names under Generic Index Rule Possibly in FY2026
  December 19, 2024

• Battle over Off-Year Price Revision Now Heading for Political Settlement
  December 13, 2024

• Discussions on Generic Company Indices Make Headway towards Full Rollout in Next Revision
  December 13, 2024

• Hearing Leaves Chuikyo Mixed on Off-Year Scheme, Political Decision Ever More Likely
  December 12, 2024

• Drug Price Gap Hits Record Low, Did Distribution Guidelines Play Any Role?
  December 10, 2024

• Chuikyo Begins Debate on Scope of FY2025 Off-Year Drug Price Revisions
  December 5, 2024

• (Update) Average NHI-Market Price Gap Narrows to 5.2% to Hit Record Low
  December 4, 2024

• Chuikyo Supports Full Rollout of Company Indices for Generics Manufacturers
  November 7, 2024

• Off-Year Debate “Won’t Progress” without Industry’s Behavioral Change: JMA Rep
  September 26, 2024

• Pharma Opposes Off-Year Revision, but Payer Pushes Implementation as Premise
  August 8, 2024

• Chuikyo Disappointed over Industry Survey on 2024 Drug Pricing Reform
  August 8, 2024

• Analysis: All Eyes Riveted on FY2024 Drug Price Survey for Off-Year Revision
  August 6, 2024

• Debates on FY2025 Off-Year Price Revision Officially Set Sail at Chuikyo
  July 18, 2024

• Industry’s Ability to Communicate Being Put to Test as Views on Off-Year Price Cuts Change
  June 11, 2024

• Japan PM Vows Early Kick Off of Off-Year Revision Debate at Chuikyo
  March 29, 2024

ページ